Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCell autologous epidermal cell suspension grafting for vitiligo and piebaldism
NL-OMON37399Active, not recruiting
- Sponsor
- Nederlands Instituut voor Pigmentstoornissen
- Start
- Aug 2012
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of ReNovaCell in Vitiligo and Piebaldism (3 arms), sponsored by Nederlands Instituut voor Pigmentstoornissen. Primary endpoints: Objective degree of repigmentation at 6 months, Visual assessment of side effects and 1 more. Started Aug 2012; status: active, not recruiting.
02
Drugs
ReNovaCell
03
Conditions
VitiligoPiebaldism
Beyond the preview
Go deeper on NL-OMON37399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37399.